Empagliflozin

Generic Name
Empagliflozin
Brand Names
Glyxambi, Jardiance, Synjardy, Trijardy
Drug Type
Small Molecule
Chemical Formula
C23H27ClO7
CAS Number
864070-44-0
Unique Ingredient Identifier
HDC1R2M35U
Background

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...

Indication

Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...

Associated Conditions
Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
Monotherapy
Clinical Trials
Related News

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

First Posted Date
2021-07-26
Last Posted Date
2022-03-18
Lead Sponsor
Getz Pharma
Target Recruit Count
123
Registration Number
NCT04976283
Locations
🇵🇰

Aga Khan University Hospital, Karachi, Sindh, Pakistan

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

First Posted Date
2021-06-24
Last Posted Date
2024-02-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16746
Registration Number
NCT04937816
Locations
🇩🇪

Boehringer Ingelheim, Ingelheim am Rhein, Germany

Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia

Phase 2
Not yet recruiting
Conditions
Glucose 6 Phosphatase Deficiency
Interventions
Drug: Empagliflozin
First Posted Date
2021-06-18
Last Posted Date
2021-06-23
Lead Sponsor
Children's Memorial Health Institute, Poland
Target Recruit Count
20
Registration Number
NCT04930627
Locations
🇵🇱

The Children's Memorial Health Institute, Warsaw, Poland

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Empagliflozin
First Posted Date
2021-06-16
Last Posted Date
2021-07-22
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
460558
Registration Number
NCT04927858
Locations
🇸🇪

Boehringer Ingelheim AB, Stockholm, Sweden

Empagliflozin in Adolescent Diabetes

Phase 4
Withdrawn
Conditions
type1diabetes
Interventions
Drug: Empagliflozin
First Posted Date
2021-06-08
Last Posted Date
2023-03-23
Lead Sponsor
Ohio State University
Registration Number
NCT04917692
Locations
🇺🇸

Ohio State University, Columbus, Ohio, United States

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

First Posted Date
2021-03-12
Last Posted Date
2021-03-12
Lead Sponsor
Center for Outcomes Research and Clinical Epidemiology, Italy
Target Recruit Count
1167
Registration Number
NCT04796428

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

First Posted Date
2021-01-11
Last Posted Date
2021-06-01
Lead Sponsor
Metacrine, Inc.
Target Recruit Count
120
Registration Number
NCT04702490
Locations
🇺🇸

Metacrine Investigative Site, San Antonio, Texas, United States

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

First Posted Date
2020-12-11
Last Posted Date
2020-12-11
Lead Sponsor
Getz Pharma
Target Recruit Count
244
Registration Number
NCT04665284
Locations
🇵🇰

Shifa International Hospital, Islamabad, Punjab, Pakistan

🇵🇰

Diabetes Institute of Pakistan, Lahore, Punjab, Pakistan

🇵🇰

Balochistan Medical Center, Quetta, Balochistan, Pakistan

and more 8 locations

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

First Posted Date
2020-10-26
Last Posted Date
2022-08-05
Lead Sponsor
EMS
Target Recruit Count
240
Registration Number
NCT04603508

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

First Posted Date
2020-10-26
Last Posted Date
2024-02-16
Lead Sponsor
EMS
Target Recruit Count
228
Registration Number
NCT04602754
Locations
🇧🇷

Allergisa, Campinas, São Paulo, Brazil

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy